Overview Dividends

(BHC) Bausch Health Companies - Ratings and Ratios

Exchange: NYSE • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA0717341071

Prescription,Surgical,Ophthalmology,Contact,Care

BHC EPS (Earnings per Share)

EPS Growth (3Y CAGR): -60.58%
EPS Trend (3Y Correlation): -30.5%

BHC Revenue

Revenue Growth (3Y CAGR): 7.62%
Revenue Trend (3Y Correlation): 76.4%

Description: BHC Bausch Health Companies August 09, 2025

Bausch Health Companies Inc (NYSE:BHC) is a Canadian pharmaceutical company. To evaluate its investment potential, we need to examine its financial health and key performance indicators (KPIs). The companys income tax expense is a crucial aspect to analyze, as it directly impacts its net income.

The pharmaceutical industry is heavily influenced by factors such as research and development (R&D) expenses, regulatory approvals, and patent expirations. BHCs market capitalization is approximately $2.14 billion, indicating a relatively mid-cap company. The price-to-earnings (P/E) ratio is 22.23, which may be considered high compared to some industry peers, suggesting potential overvaluation or high growth expectations.

Key economic drivers for BHC include the demand for its pharmaceutical products, pricing power, and competition. The companys return on equity (RoE) is not available, which is a significant omission, as it is a crucial metric for evaluating profitability. To better understand BHCs financial performance, we need to examine its revenue growth, operating margins, and cash flow generation.

Some essential KPIs to monitor for BHC include revenue growth rate, gross margin percentage, operating cash flow margin, and debt-to-equity ratio. Analyzing these metrics will provide insights into the companys ability to generate cash, manage its debt, and maintain profitability. Additionally, we should track industry trends, such as the adoption of generic drugs and the impact of regulatory changes on the pharmaceutical landscape.

BHC Stock Overview

Market Cap in USD	2,300m
Sub-Industry	Pharmaceuticals
IPO / Inception	1994-03-29

BHC Stock Ratings

Growth Rating	-41.1%
Fundamental	58.5%
Dividend Rating	4.23%
Return 12m vs S&P 500	-36.6%
Analyst Rating	3.0 of 5

BHC Dividends

Currently no dividends paid

BHC Growth Ratios

Growth Correlation 3m	-29.4%
Growth Correlation 12m	-54%
Growth Correlation 5y	-75.2%
CAGR 5y	-1.58%
CAGR/Max DD 3y (Calmar Ratio)	-0.03
CAGR/Mean DD 3y (Pain Ratio)	-0.06
Sharpe Ratio 12m	-0.68
Alpha	-34.21
Beta	0.433
Volatility	55.19%
Current Volume	1273.6k
Average Volume 20d	1401.7k
Stop Loss	5.9 (-4.8%)
Signal	-0.22

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (98.0m TTM) > 0 and > 6% of Revenue (6% = 589.9m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 0.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 15.65% (prev 9.16%; Δ 6.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 1.51b > Net Income 98.0m (YES >=105%, WARN >=100%)

Net Debt (20.01b) to EBITDA (2.91b) ratio: 6.88 <= 3.0 (WARN <= 3.5)

Current Ratio 1.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (373.1m) change vs 12m ago 0.78% (target <= -2.0% for YES)

Gross Margin 75.37% (prev 92.30%; Δ -16.93pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 36.58% (prev 34.69%; Δ 1.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.34 (EBITDA TTM 2.91b / Interest Expense TTM 1.48b) >= 6 (WARN >= 3)

Altman Z'' -0.34

(A) 0.06 = (Total Current Assets 6.51b - Total Current Liabilities 4.97b) / Total Assets 27.27b

(B) -0.36 = Retained Earnings (Balance) -9.73b / Total Assets 27.27b

(D) -0.04 = Book Value of Equity -1.01b / Total Liabilities 27.12b

Total Rating: -0.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 58.49

1. Piotroski 2.50pt = -2.50

2. FCF Yield 5.03% = 2.51

3. FCF Margin 11.41% = 2.85

4. Debt/Equity -28.45 = -2.50

5. Debt/Ebitda 6.88 = -2.50

6. ROIC - WACC (= 6.33)% = 7.91

7. RoE -8.91% = -1.48

8. Rev. Trend 76.36% = 5.73

9. EPS Trend -30.51% = -1.53

What is the price of BHC shares?

As of October 28, 2025, the stock is trading at USD 6.20 with a total of 1,273,572 shares traded.
Over the past week, the price has changed by -1.74%, over one month by -4.17%, over three months by -10.01% and over the past year by -24.30%.

Is Bausch Health Companies a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Bausch Health Companies is currently (October 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 58.49 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BHC is around 5.65 USD . This means that BHC is currently overvalued and has a potential downside of -8.87%.

Is BHC a buy, sell or hold?

Bausch Health Companies has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold BHC.

Strong Buy: 0
Buy: 1
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the BHC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	7.1	14.2%
Analysts Target Price	7.1	14.2%
ValueRay Target Price	6	-3.9%

BHC Fundamental Data Overview October 27, 2025

Market Cap USD = 2.30b (2.30b USD * 1.0 USD.USD)
P/E Trailing = 23.8462
P/E Forward = 1.5825
P/S = 0.2333
P/B = 18.7773
P/EG = 0.6315
Beta = 0.433
Revenue TTM = 9.83b USD
EBIT TTM = 1.98b USD
EBITDA TTM = 2.91b USD
Long Term Debt = 20.86b USD (from longTermDebt, last quarter)
Short Term Debt = 879.0m USD (from shortTermDebt, last quarter)
Debt = 21.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 20.01b USD (from netDebt column, last quarter)
Enterprise Value = 22.31b USD (2.30b + Debt 21.74b - CCE 1.73b)
Interest Coverage Ratio = 1.34 (Ebit TTM 1.98b / Interest Expense TTM 1.48b)
FCF Yield = 5.03% (FCF TTM 1.12b / Enterprise Value 22.31b)
FCF Margin = 11.41% (FCF TTM 1.12b / Revenue TTM 9.83b)
Net Margin = 1.00% (Net Income TTM 98.0m / Revenue TTM 9.83b)
Gross Margin = 75.37% ((Revenue TTM 9.83b - Cost of Revenue TTM 2.42b) / Revenue TTM)
Gross Margin QoQ = 99.36% (prev 68.97%)
Tobins Q-Ratio = 0.82 (Enterprise Value 22.31b / Total Assets 27.27b)
Interest Expense / Debt = 2.14% (Interest Expense 465.0m / Debt 21.74b)
Taxrate = 8.57% (12.2m / 142.3m)
NOPAT = 1.81b (EBIT 1.98b * (1 - 8.57%))
Current Ratio = 1.31 (Total Current Assets 6.51b / Total Current Liabilities 4.97b)
Debt / Equity = -28.45 (negative equity) (Debt 21.74b / totalStockholderEquity, last quarter -764.0m)
Debt / EBITDA = 6.88 (Net Debt 20.01b / EBITDA 2.91b)
Debt / FCF = 17.84 (Net Debt 20.01b / FCF TTM 1.12b)
Total Stockholder Equity = -1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.36% (Net Income 98.0m / Total Assets 27.27b)
RoE = -8.91% (negative equity) (Net Income TTM 98.0m / Total Stockholder Equity -1.10b)
RoCE = 10.01% (EBIT 1.98b / Capital Employed (Equity -1.10b + L.T.Debt 20.86b))
RoIC = 8.82% (NOPAT 1.81b / Invested Capital 20.49b)
WACC = 2.50% (E(2.30b)/V(24.04b) * Re(7.61%) + D(21.74b)/V(24.04b) * Rd(2.14%) * (1-Tc(0.09)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈1.04b ; Y1≈679.6m ; Y5≈310.8m
Fair Price DCF = 16.52 (DCF Value 6.11b / Shares Outstanding 369.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -30.51 | EPS CAGR: -60.58% | SUE: -3.19 | # QB: 0
Revenue Correlation: 76.36 | Revenue CAGR: 7.62% | SUE: 0.32 | # QB: 0

Additional Sources for BHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle